Your browser doesn't support javascript.
Animal models for COVID-19.
Muñoz-Fontela, César; Dowling, William E; Funnell, Simon G P; Gsell, Pierre-S; Riveros-Balta, A Ximena; Albrecht, Randy A; Andersen, Hanne; Baric, Ralph S; Carroll, Miles W; Cavaleri, Marco; Qin, Chuan; Crozier, Ian; Dallmeier, Kai; de Waal, Leon; de Wit, Emmie; Delang, Leen; Dohm, Erik; Duprex, W Paul; Falzarano, Darryl; Finch, Courtney L; Frieman, Matthew B; Graham, Barney S; Gralinski, Lisa E; Guilfoyle, Kate; Haagmans, Bart L; Hamilton, Geraldine A; Hartman, Amy L; Herfst, Sander; Kaptein, Suzanne J F; Klimstra, William B; Knezevic, Ivana; Krause, Philip R; Kuhn, Jens H; Le Grand, Roger; Lewis, Mark G; Liu, Wen-Chun; Maisonnasse, Pauline; McElroy, Anita K; Munster, Vincent; Oreshkova, Nadia; Rasmussen, Angela L; Rocha-Pereira, Joana; Rockx, Barry; Rodríguez, Estefanía; Rogers, Thomas F; Salguero, Francisco J; Schotsaert, Michael; Stittelaar, Koert J; Thibaut, Hendrik Jan; Tseng, Chien-Te.
  • Muñoz-Fontela C; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
  • Dowling WE; German Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
  • Funnell SGP; Centre for Epidemic Preparedness Innovations (CEPI), Washington, DC, USA.
  • Gsell PS; National Infection Service, Public Health England, Salisbury, UK.
  • Riveros-Balta AX; World Health Organization, Geneva, Switzerland.
  • Albrecht RA; World Health Organization, Geneva, Switzerland.
  • Andersen H; Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Baric RS; Bioqual Inc, Rockville, MD, USA.
  • Carroll MW; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Cavaleri M; National Infection Service, Public Health England, Salisbury, UK.
  • Qin C; European Medicines Agency, Amsterdam, The Netherlands.
  • Crozier I; Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking, China.
  • Dallmeier K; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • de Waal L; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
  • de Wit E; Viroclinics Xplore, Schaijk, The Netherlands.
  • Delang L; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
  • Dohm E; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
  • Duprex WP; Animal Resources Program, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Falzarano D; Department of Microbiology and Molecular Genetics, Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.
  • Finch CL; VIDO-Intervac, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
  • Frieman MB; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA.
  • Graham BS; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Gralinski LE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Guilfoyle K; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Haagmans BL; Viroclinics Xplore, Schaijk, The Netherlands.
  • Hamilton GA; Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Hartman AL; Emulate Inc, Boston, MA, USA.
  • Herfst S; Department of Microbiology and Molecular Genetics, Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.
  • Kaptein SJF; Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Klimstra WB; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
  • Knezevic I; Department of Immunology, Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.
  • Krause PR; World Health Organization, Geneva, Switzerland.
  • Kuhn JH; Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA.
  • Le Grand R; Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA.
  • Lewis MG; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Inserm, CEA, Université Paris-Saclay, Paris, France.
  • Liu WC; Bioqual Inc, Rockville, MD, USA.
  • Maisonnasse P; Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • McElroy AK; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Inserm, CEA, Université Paris-Saclay, Paris, France.
  • Munster V; Division of Pediatric Infectious Diseases, Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Oreshkova N; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
  • Rasmussen AL; Wageningen Bioveterinary Research (WBVR), Wageningen University and Research, Lelystad, The Netherlands.
  • Rocha-Pereira J; Center for Infection and Immunity, Columbia Mailman |School of Public Health, New York, NY, USA.
  • Rockx B; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
  • Rodríguez E; Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Rogers TF; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
  • Salguero FJ; German Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
  • Schotsaert M; Division of Infectious Diseases, University of California San Diego, San Diego, CA, USA.
  • Stittelaar KJ; National Infection Service, Public Health England, Salisbury, UK.
  • Thibaut HJ; Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Tseng CT; Viroclinics Xplore, Schaijk, The Netherlands.
Nature ; 586(7830): 509-515, 2020 10.
Article in English | MEDLINE | ID: covidwho-792975
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the introduction of a novel coronavirus into humans late in 2019 (first detected in Hubei province, China). As of 18 September 2020, SARS-CoV-2 has spread to 215 countries, has infected more than 30 million people and has caused more than 950,000 deaths. As humans do not have pre-existing immunity to SARS-CoV-2, there is an urgent need to develop therapeutic agents and vaccines to mitigate the current pandemic and to prevent the re-emergence of COVID-19. In February 2020, the World Health Organization (WHO) assembled an international panel to develop animal models for COVID-19 to accelerate the testing of vaccines and therapeutic agents. Here we summarize the findings to date and provides relevant information for preclinical testing of vaccine candidates and therapeutic agents for COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Disease Models, Animal / Pandemics Type of study: Etiology study Topics: Vaccines Limits: Animals / Humans Language: English Journal: Nature Year: 2020 Document Type: Article Affiliation country: S41586-020-2787-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Disease Models, Animal / Pandemics Type of study: Etiology study Topics: Vaccines Limits: Animals / Humans Language: English Journal: Nature Year: 2020 Document Type: Article Affiliation country: S41586-020-2787-6